%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-10-07T07:22:30-04:00
2016-10-07T07:23:05-04:00
2016-10-07T07:23:05-04:00
Adobe InDesign CC 2015 (Windows)
uuid:2712a1b0-0bc8-439b-a9d3-7433f4d369f6
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:5ce8cd2f-5af3-5043-8fbd-79bfa7fc548b
proof:pdf
xmp.iid:381f40b4-304d-3341-813f-9a96b6681961
xmp.did:e49a6453-b4b6-7044-a225-9ef9ac530f49
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2015 (Windows)
/
2016-10-07T07:22:30-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
19 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1 (rimary Care)]TJ
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 373.76 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 158.4884 373.76 Tm
(\231 )Tj
1.23 0 Td
( )Tj
-0.01 Tc -20.853 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2016)-9.9 ( )]TJ
0 -1.167 TD
[(AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
8 0 0 8 40.75 349.76 Tm
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
0 -1.25 TD
(Physician Editor:)Tj
/T1_1 1 Tf
( Stephen Brunton, MD)Tj
/T1_2 1 Tf
T*
(Assistant Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 315.76 Tm
[(This is an educational publication designed to present)-10 ( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-10 ( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-10 ( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment)-10 ( )]TJ
T*
(for any individual case. It is not intended for the layman.)Tj
0.01 Tc 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.025 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-25 ( )]TJ
-0.001 Tw T*
[(accordance with Accreditation Council for Continuing Medical)-25 ( )]TJ
0 Tw 0 -1.167 TD
[(Education guidelines, Dr. Brunton reports he is a retained)-25 ( )]TJ
0 -1.167 TD
[(consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton)-25 ( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly,)-25 ( )]TJ
0 -1.167 TD
[(Merck, Novo Nordisk, Sanofi, and Teva; he serves on the)-25 ( )]TJ
0 -1.167 TD
[(speakers bureau of AstraZeneca, Boehringer Ingelheim,)-25 ( )]TJ
T*
[(Janssen, Lilly, Novo Nordisk, and Teva. Dr. Kuritzky reports)-25 ( )]TJ
0 -1.167 TD
[(he is a retained advisor/consultant for AbbVie, Allergan,)-24.9 ( )]TJ
0 -1.167 TD
[(AstraZeneca, Janssen, Lilly, Lundbeck, Medscape, Novo)-25 ( )]TJ
T*
[(Nordisk, and Sanofi Aventis, and serves on the speakers)-25 ( )]TJ
0 -1.167 TD
[(bureau of Lilly and Lundbeck. Ms. Coplin and Mr. Springston)-25 ( )]TJ
0 -1.167 TD
(report no financial relationships relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 165.734 338.51 re
S
/CS0 cs 0.1 scn
43.545 100.88 146.91 68.76 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 87.0262 140.0642 cm
0 0 m
97.973 0 l
S
Q
q 1 0 0 1 72.6205 133.0642 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 157.9401 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 147.6641 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
-0.025 Tc 6 0 0 6 48.0448 140.6641 Tm
(Email Address: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
0.025 Tw (Jonathan.Springston@AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
-0.01 Tc 0.01 Tw T*
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One)-10 ( )]TJ
T*
[(Atlanta Plaza, 950 East Paces Ferry Road NE, Suite)-10 ( )]TJ
T*
[(2850, Atlanta, GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
81.64 48.558 70.72 32.442 re
W n
/GS1 gs
q 1 0 0 1 88.9838 67.8133 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 107.4452 61.2239 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 125.1715 63.7154 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 132.7822 63.9877 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 140.1476 63.8379 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
143.619 66.602 1.675 -6.63 re
143.619 59.971 m
145.403 68.453 m
145.403 67.963 145.036 67.555 144.45 67.555 c
143.892 67.555 143.524 67.963 143.524 68.453 c
143.524 68.971 143.906 69.365 144.464 69.365 c
145.036 69.365 145.39 68.971 145.403 68.453 c
f
q 1 0 0 1 150.6175 63.2117 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
/CS0 CS 1 SCN
1 w
/GS1 gs
q 1 0 0 1 36 601.3882 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 550.1613 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/T1_3 1 Tf
0.01 Tc 9 0 0 9 36 737.0496 Tm
[(on a population-wide basis. Instead,)10 ( )]TJ
0 -1.213 TD
(USPSTF recommends screening in high-)Tj
0 -1.213 TD
[(risk populations. Such individuals include)10.1 ( )]TJ
0 -1.213 TD
[(persons who have lived in countries of)10 ( )]TJ
0 -1.213 TD
(high TB prevalence \(e.g., Mexico, Philip)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.213 TD
[(pines, V)37 (ietnam, India, China, Haiti,)10 ( )]TJ
0 -1.213 TD
[(or Guatemala\), have lived in high-risk)10 ( )]TJ
0 -1.213 TD
(congregate settings \(e.g., homeless/correc)Tj
0 Tc (-)Tj
0.01 Tc T*
[(tional facilities\), are immunosuppressed)10 ( )]TJ
0 -1.213 TD
[(\(e.g., HIV or on immunosuppressive)10 ( )]TJ
T*
[(meds\), and have been in contact with)9.9 ( )]TJ
0 -1.213 TD
[(persons suffering from active TB. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 172.9694 617.0016 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 36 587.3882 Tm
(Gabapentin and)Tj
0 Tc 6.263 0 Td
( )Tj
-0.005 Tc -6.263 -1.151 Td
[(P)17.6 (regabalin Effective for)]TJ
0 Tc 9.166 0 Td
( )Tj
-0.005 Tc -9.166 -1.151 Td
[(R)17.6 (efractory Chronic P)17.5 (ruritus)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 36 532.2479 Tm
(SOURCE: Matsuda K, Sharma D, Schonfeld )Tj
T*
(AR, Kwatra SG. Gabapentin and pregabalin for )Tj
0 -1.213 TD
(the treatment of chronic pruritus. )Tj
/TT2 1 Tf
[(J Am A)-18.2 (cad )]TJ
0 -1.213 TD
(Dermatol)Tj
/TT1 1 Tf
( 2016;75:619-625.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 34.9043 468.7941 Tm
(C)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 56.2474 479.5941 Tm
[(linicians usually are successful when)10 ( )]TJ
0 -1.2 TD
(they treat pruritus with antihista)Tj
0 Tc (-)Tj
0.01 Tc -2.25 -1.213 Td
[(mines. Some categories of pruritus prove)10 ( )]TJ
0 -1.213 TD
[(somewhat refractory to intervention,)10 ( )]TJ
0 -1.213 TD
[(such as uremic pruritus and neurogenic)10.1 ( )]TJ
0 -1.213 TD
[(pruritus. When traditional antihistamines)10 ( )]TJ
0 -1.213 TD
[(\(e.g., diphenhydramine, hydroxyzine,)10 ( )]TJ
0 -1.213 TD
[(cetirizine, loratadine\) have failed, what)10 ( )]TJ
0 -1.213 TD
(else might work?)Tj
ET
/GS1 gs
q 1 0 0 1 214.008 447.0894 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 411.9178 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 214.008 737.0496 Tm
[(Gabapentin and pregabalin are analogues)10 ( )]TJ
0 -1.219 TD
[(of gamma-aminobutyric acid, but do not)10 ( )]TJ
T*
(actually interact with gamma-aminobu)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(tyric acid receptors. They generally are)10 ( )]TJ
0 -1.219 TD
[(well tolerated, and although originally)10 ( )]TJ
0 -1.219 TD
(investigated for their antiepileptic poten)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(tial, the authors addressed 37 different)9.9 ( )]TJ
0 -1.219 TD
(randomized, controlled trials of gaba)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(pentin, pregabalin, or the combination)10 ( )]TJ
0 -1.219 TD
[(in a variety of different itch syndromes.)9.9 ( )]TJ
0 -1.219 TD
(Gabapentin and pregabalin were dem)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(onstrated to produce substantial clinical)10 ( )]TJ
T*
[(success in syndromes as far ranging as)9.9 ( )]TJ
T*
[(uremic pruritus, notalgia paresthetica,)10 ( )]TJ
T*
[(post-spinal cord pruritus, and cancer)10 ( )]TJ
T*
(chemotherapy-related pruritus.)Tj
0 -2.438 TD
(The tolerability of gabapentin and prega)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
(balin was re\036ected in the modest dis)Tj
0 Tc (-)Tj
0.01 Tc T*
[(continuation rates due to adverse effects)10 ( )]TJ
T*
[(\(6-8%\). Although most of the trials were)10 ( )]TJ
T*
[(small and lacked long-term follow-up,)10 ( )]TJ
0 -1.219 TD
(the promising results support consider)Tj
0 Tc 16.829 0 Td
(-)Tj
0.01 Tc -16.829 -1.219 Td
[(ation of gabapentin, pregabalin, or both)10 ( )]TJ
T*
[(for patients presenting with refractory)10 ( )]TJ
-0.01 Tw 0 -1.219 TD
(pruritus. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 0 Tw 10 0 0 10 253.3377 462.7609 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 433.0894 Tm
[(Does T)175 (echnology Accelerate)-4.8 ( )]TJ
0 -1.155 TD
[(W)54.5 (eight Loss?)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 214.008 393.9463 Tm
[(SOURCE: Jakicic JM, Davis KK, R)16.8 (ogers RJ, et al. )]TJ
0 -1.219 TD
(Effect of wearable technology combined with )Tj
T*
(a lifestyle intervention on long-term weight )Tj
T*
(loss: The IDEA randomized clinical trial. )Tj
/TT2 1 Tf
15.337 0 Td
(JAMA)Tj
/TT1 1 Tf
( )Tj
-15.337 -1.219 Td
(2016;316:1161-1171.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 211.787 319.2886 Tm
(F)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 227.3409 330.0886 Tm
[(or most of patients, long-term weight)10.1 ( )]TJ
0 -1.2 TD
[(loss is modest, whether they use diet,)10 ( )]TJ
-0.005 Tw -1.481 -1.219 Td
[(exercise, )0.6 (pharmacotherapy)92 (, )0.6 (or )0.5 (a )0.5 (combina)]TJ
0 Tc 0 Tw (-)Tj
0.01 Tc 0 -1.219 TD
[(tion. Only bariatric surgical interventions)10 ( )]TJ
T*
(provide consistent and sustained substan)Tj
0 Tc (-)Tj
0.01 Tc T*
[(tial weight loss \(> 20%\) for the majority)10 ( )]TJ
T*
[(of patients. In this age of technological)10 ( )]TJ
T*
[(advances, will sophisticated tools lead)10 ( )]TJ
T*
(our patients to enhanced weight loss?)Tj
0 -2.438 TD
[(Jakicic et al enrolled overweight and)10 ( )]TJ
0 -1.219 TD
[(obese adults \(n = 471\) in a randomized)10 ( )]TJ
0 -1.219 TD
[(trial comparing traditional interventions,)10 ( )]TJ
0 -1.219 TD
[(such as education about diet, exercise,)10 ( )]TJ
0 -1.219 TD
(and counseling, with traditional interven)Tj
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
[(tions plus gadgetry)92 (, which included wear)]TJ
0 Tc 17.925 0 Td
(-)Tj
0.01 Tc -17.925 -1.219 Td
[(able devices to monitor physical activity)10 ( )]TJ
-0.002 Tw 0 -1.219 TD
[(and a web-based interface to monitor diet)10 ( )]TJ
0 Tw 0 -1.219 TD
[(and activity)92 (. The authors analyzed the ef)]TJ
0 Tc (-)Tj
0.01 Tc 0 -1.219 TD
(fect of the added gadgetry at 24 months.)Tj
0 -2.438 TD
[(Although both groups enjoyed weight)10 ( )]TJ
0 -1.219 TD
[(loss at the conclusion of the 24-month)9.9 ( )]TJ
T*
[(intervention, the group randomized to)10 ( )]TJ
T*
(add-on gadgetry actually experienced )Tj
/T1_4 1 Tf
-0.01 Tw (less)Tj
/T1_3 1 Tf
0 Tc 0 Tw 18.291 0 Td
( )Tj
0.01 Tc -18.291 -1.219 Td
(weight loss than the group that simply re)Tj
0 Tc (-)Tj
0.01 Tc T*
[(ceived traditional diet and exercise advice)10.1 ( )]TJ
ET
/GS1 gs
q 1 0 0 1 392.016 678.3495 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 643.3495 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 392.016 737.0496 Tm
[(\(3.6% vs. 6.2%\). Previous shorter)55 (-term)10 ( )]TJ
0 -1.2 TD
[(studies have been more supportive of)10 ( )]TJ
0 -1.2 TD
[(wearable devices, but perhaps the gloss)10.1 ( )]TJ
0 -1.2 TD
[(wears off in longer)55 (-term studies such as)10 ( )]TJ
-0.01 Tw T*
[(this )-10 (one. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 0 Tw 10 0 0 10 430.8417 693.8495 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 664.3495 Tm
[(The Importance of Low Uric)-5 ( )]TJ
0 -1.143 TD
[(Acid in Gout P)35.7 (atients)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 392.016 625.5496 Tm
[(SOURCE: R)17.4 (uoff G, Edwards NL. Overview of )]TJ
0 -1.2 TD
(serum uric acid treatment targets in gout: Why )Tj
0 -1.2 TD
(less than 6 mg/dL? )Tj
/TT2 1 Tf
[(P)54.6 (ostgrad Med)]TJ
/TT1 1 Tf
( 2016;128:)Tj
16.627 0 Td
( )Tj
-16.627 -1.2 Td
(706-715.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 389.7062 562.5496 Tm
(I)Tj
/T1_3 1 Tf
0.01 Tc 9 0 0 9 397.5903 573.3495 Tm
[(n addition to the burden caused by)10 ( )]TJ
0 -1.2 TD
[(painful acute gout \036ares, inadequately)10 ( )]TJ
-0.619 -1.2 Td
[(managed gout can lead to substantial)10 ( )]TJ
T*
[(long-term disability and deformity)92 (. Not)10 ( )]TJ
T*
[(everyone presenting with hyperuricemia)10 ( )]TJ
T*
[(develops gout or requires treatment.)10 ( )]TJ
-0.01 Tw T*
(Indeed, )Tj
/T1_5 1 Tf
0 Tc 0 Tw 3.524 0 Td
(\036)Tj
/T1_3 1 Tf
0.01 Tc 0.589 0 Td
[( 10% of patients demonstrating)10 ( )]TJ
-4.113 -1.2 Td
[(marked elevation in serum uric acid)10 ( )]TJ
0 Tc 16.083 0 Td
( )Tj
0.01 Tc -16.083 -1.2 Td
(\(> 9.0 mg/dL\) go on to develop gout an)Tj
0 Tc (-)Tj
0.01 Tc T*
[(nually)92 (. Once patients experience diathesis)10.1 ( )]TJ
T*
[(to deposit in\036ammatory urate crystals in)9.9 ( )]TJ
T*
[(joints \(or other tissues\) during a single)10 ( )]TJ
T*
(attack of gout, )Tj
/T1_5 1 Tf
0 Tc (\037)Tj
/T1_3 1 Tf
0.01 Tc 7.361 0 Td
[( 90% will suffer another)10 ( )]TJ
-7.361 -1.2 Td
[(attack within 10 years, suggesting that)10 ( )]TJ
T*
[(most sufferers will not be so lucky as to)10 ( )]TJ
T*
(experience a one-time event.)Tj
0 -2.4 TD
[(In vitro, crystals tend to form when uric)10 ( )]TJ
0 -1.2 TD
(acid levels exceed about 6.8 mg/dL, re)Tj
0 Tc (-)Tj
0.01 Tc T*
[(\036ecting saturation at that point. V)86 (arious)10 ( )]TJ
T*
[(guidelines suggest clinicians treating gout)10 ( )]TJ
T*
[(should aim for a lowering to a minimum)10 ( )]TJ
T*
[(of 6.0 mg/dL, noting that sustained uric)10 ( )]TJ
T*
[(acid lowering ultimately is associated)10 ( )]TJ
T*
[(with a disappearance of \036ares as well as a)10 ( )]TJ
T*
[(dissolution of tissue deposits of uric acid)10 ( )]TJ
T*
[(\(e.g., tophi\). Indeed, the rate of tophus)10 ( )]TJ
T*
(dissolution has been shown to be propor)Tj
0 Tc 17.899 0 Td
(-)Tj
0.01 Tc -17.899 -1.2 Td
[(tional to the degree of lowering of serum)10 ( )]TJ
T*
(uric acid levels.)Tj
0 -2.4 TD
[(Although clinicians might be tempted to)9.9 ( )]TJ
0 -1.2 TD
[(aim for a goal just below 6.8 mg/dL, it)10 ( )]TJ
T*
[(is probably unwise to do so. Dietary and)10 ( )]TJ
T*
(physiologic changes may cause \036uctua)Tj
0 Tc (-)Tj
0.01 Tc T*
[(tion substantially above 6.8 mg/dL unless)10 ( )]TJ
0 -1.2 TD
[(a wide margin of safety is created. T)36.9 (issue)10 ( )]TJ
0 -1.2 TD
[(deposition of uric acid can cause chronic)10 ( )]TJ
0 -1.2 TD
[(silent joint destruction at elevated levels)10 ( )]TJ
T*
[(of uric acid. Consistent abolition of acute)10 ( )]TJ
T*
[(\036ares has been con\037rmed only when uric)10.1 ( )]TJ
T*
[(acid levels < 6.0 mg/dL are maintained)10 ( )]TJ
T*
[(over the long term. )10 ( )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 472.7272 119.7495 Tm
<0084>Tj
ET
endstream
endobj
25 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
24 0 obj
<>
endobj
26 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
11 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
12 0 obj
<>
endobj
23 0 obj
<>
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
16 0 obj
<>
endobj
17 0 obj
<>
endobj
47 0 obj
<>
endobj
48 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
49 0 obj
<>stream
HtU TSW['}MqRDQ(jYCDkqkZZHJ-jF\U.uCOi303dD99}#iZrv]v7$KWS|x!
̼rկF
Kf9DG
kyщ1ğhstcםJzHY@DY PJ0||2S^X7MTduQNu UdS?./g!?7\l$Ud~~I?d{qp 0rBeg#p'Xqp./9'qb cH́YN-Z1" 4_Q"YY;J'gW7wO/o_Z7? ppАÂi#FDF5zؿz츸&N<%ajⴤ3SH}3-=㭙ogfe 7OU0{¢y%+*kYnE,}e,_Uխ^u?Pq-6}u͟s/|u7{C;q3gϝpKroܼ;wzGHGAX2ea,%Vu9?
PFv5G3T3Q9g2kLle,|k,w$h/qf/L&O?DLLMN?X kYr~p`$C-\KVQb-s,dZe8z<XUL>6zt_Fi?фv|8V"kwy\\e|C\5|Yxq`%`6(F)J0e@9*Q_PwPŻ8mXDY%0)P^!c&G#Cܡ3Gta/
AӼKq
t_bj,߾f` 6IH%:^R(C'
B+GΑu&
WB@&e`&Y#Ch'"u`,=D&BO6)}4XteL )eFj2:,Ub
i;2^UyiE#5H$EX8vy"ntFUIŽ\0#jPNU5I]\5`\j:ł'%k`M&HeXD1kdh拑(lH'K)G]ZɗU|xS˄ CdH;DxaJOҵLOSOWKUmHjQ2O1Mjem?S>6%)Mvc|@q$KN#1Ӊ7zNe)bNH:LLRb1Ai4*jZ/=/ (ŔTAs1JHR7@`/(3iWD+(pP2
,ZUtoq@Ǘb%w<0A&kk~1?kC2}bË\(/VĘOdx[Jw;N*8+|}<=]]
Uy|TKӮ3ƠFN5mL`- ce2D]0ΰ{{;gV\t`Mo?LnpՆV1 >YG*KHHe]2:4GJa؋}\RknV˨s95s)>袖-&dZ3VvƂG1r9J\8+vlj7h]1{v˦hZN1HzbcQtxMkdIݘ)urOn3:oMW}KW?iMQ_ͱ+2\YioS@OEOj<9d-|&pDFNh(C!BVs*b5jwa7"xKbc7::f|e$ 5y"6Ah5Xt,aNH&b[#aieYn Q;hP̂5q-<%k0҆:)h zL { >&$r
+ ajmkfH=|jvuӸD>UJE/94Wɷ
8JҞoj}FC^7uqw
n2_t>KҩAgjy]y.Dn|rs.E#IN!ɅnLi j"rjTHSU.lELyRFUKO"cYp#IqW(?4πpxP$yդ\
!]nxV[usnMl^YBb2'`Z41`1d4k2ةJ!١+n%;:"/iuv}Lh߅J'If:eʉ-܀xyo8.,Vn:~mѼc濳AҫWxTj9]vgsΑ6"%贪J( D'iy$bŖhh>1ϲ۱>i `# u5Ⴝ!njӴ'XG
;\$gh-` IOc \ UhkR_j0I 8$AFX3PVoxoz?ҺAF~n(=29PTA7]wIMWl-ԏvN1?7ڻu:ߡ
+
$ݳ|
ΆjPt4(UTӨF+]Tz,zc6`7uɤ8|dlGf8He.r
:>UK<|dLj$.`3
$h61gBY( UIp;
?(+MbAP);Rg+&Sufda '_qd$kp?_fO7BelR_bQE
&V;Uld͢hr,4]/DzzeK1÷sur=ٱtr-~e